Avita Medical
1st Floor, Unex House
132-134 Hills Road
Cambridge
CB2 8PA
United Kingdom
Tel: 44-0-1223 341150
Fax: 44-0-1223-341170
Website: http://www.avitamedical.com/
Email: info.eu@avitamedical.com
276 articles about Avita Medical
-
AVITA Medical Submits FDA PMA Supplement for RECELL GO
6/29/2023
AVITA Medical, Inc. announced its submission of a premarket approval supplement to the U.S. Food and Drug Administration for RECELL GO™.
-
AVITA Medical Rejoins the Russell 3000 Index
6/26/2023
AVITA Medical, Inc. announced that it has rejoined the broad-market Russell 3000® Index following the conclusion of the 2023 Russell indexes annual reconstitution, effective after the U.S. market opens on June 26, 2023.
-
AVITA Medical Announces FDA Approval of RECELL for Skin Repigmentation in Vitiligo Patients
6/16/2023
AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) today announced that the U.S. Food and Drug Administration (FDA) has approved its application for premarket approval (PMA) of its RECELL® System for the treatment of vitiligo.
-
AVITA Medical Announces Appointment of David O’Toole as Chief Financial Officer
6/15/2023
AVITA Medical, Inc. announced the appointment of David O’Toole as its new Chief Financial Officer, effective June 15, 2023.
-
AVITA Medical Reports First Quarter 2023 Financial Results and Affirms Full Year Guidance
5/11/2023
AVITA Medical, Inc., a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, reported financial results for the first quarter March 31, 2023.
-
AVITA Medical to Announce First Quarter 2023 Financial Results
4/20/2023
AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) announced today that it will report its first quarter 2023 financial results after the close of the U.S. financial markets on Thursday, May 11, 2023.
-
AVITA Medical Announces Update to Automation Device
4/13/2023
AVITA Medical, Inc. announced that its automated device, RECELL GO, maintains the Food and Drug Administration Breakthrough Device designation for the treatment of acute wounds.
-
AVITA Medical Appoints New Non-Executive Member to the Board of Directors
3/16/2023
AVITA Medical, Inc. announced the appointment of Cary Vance to its Board of Directors, effective April 1, 2023.
-
AVITA Medical to Present at the TD Cowen 43rd Annual Health Care Conference
3/2/2023
AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, announced today that Jim Corbett, Chief Executive Officer, will present at the TD Cowen 43rd Annual Health Care Conference in Boston on Tuesday, March 7, 2023, at 9:10 a.m. Eastern Time.
-
AVITA Medical Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Financial Guidance
2/23/2023
AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today reported financial results for the fourth quarter and full-year ended December 31, 2022.
-
AVITA Medical to Announce Fourth Quarter and Full Year 2022 Financial Results and Provide 2023 Financial Guidance
2/9/2023
AVITA Medical, Inc. announced that it will report its fourth quarter and full year 2022 financial results after the close of the U.S. financial markets on Thursday, February 23, 2023.
-
AVITA Medical Announces Management Changes and Fourth Quarter 2022 Earnings Conference Call
1/19/2023
AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical” or the “Company”), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, announced today changes to its management structure designed to advance its strategic growth plans and accelerate execution under recently appointed Chief Executive Officer, James Corbett
-
AVITA Medical Submits FDA PMA Application to Expand Indication to Vitiligo
12/19/2022
AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, announced today the submission of a Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for its RECELL® System.
-
AVITA Medical Announces Results of 2022 Annual Meeting of Stockholders
12/13/2022
AVITA Medical, Inc., a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, announced the results of its 2022 Annual Meeting of Stockholders, which was held virtually on December 12, 2022 .
-
AVITA Medical Submits FDA PMA Supplement to Further Expand Indication to Soft Tissue Repair
12/12/2022
AVITA Medical, Inc. announced today the submission of a Premarket Approval (PMA) supplement application to the U.S. Food and Drug Administration (FDA) for the company’s RECELL ® System.
-
AVITA Medical® to Present at the Piper Sandler 34th Annual Healthcare Conference
11/21/2022
AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, announced today that its management team will present at the Piper Sandler 34th Annual Healthcare Conference in New York on Wednesday, November 30, 2022, at 4:30 p.m. Eastern Time.
-
AVITA Medical® to Host Investor Webinar Briefing
11/16/2022
AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, invites shareholders and prospective investors to attend its investor webinar briefing and presentation by Jim Corbett, CEO, and Michael Holder, CFO, on November 23, 2022 at 4:00pm (PST) / November 24, 2022 at 11:00am (AEDT).
-
AVITA Medical Reports Third Quarter 2022 Financial Results
11/10/2022
AVITA Medical, Inc. reported financial results for the third quarter ended September 30, 2022.
-
AVITA Medical Announces Achievement of Co-Primary Endpoints in Updated Analysis of Pivotal Trial of RECELL® System for Soft Tissue Repair
11/9/2022
AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) today announced achievement of co-primary endpoints as a result of updated analysis of data from its clinical trial evaluating the safety and effectiveness of the RECELL® System for soft tissue repair.
-
AVITA Medical Announces FDA Breakthrough Device Designations for the RECELL® System
11/3/2022
AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) announced today that the Food and Drug Administration (FDA) granted the RECELL System designations as a Breakthrough Device for its proposed soft tissue repair indication as well as its vitiligo indication.